luliconazole 10% solution (SKX-16) / Sato Pharma, Bausch Health - LARVOL DELTA

Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis (clinicaltrials.gov) - P1 | N=19 | Completed | Sponsor: SATO Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease

Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: SATO Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease

Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: SATO Pharmaceutical Co., Ltd. | Trial completion date: Feb 2022 ➔ Feb 2023 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Infectious Disease

Safety and Tolerability Study of SKX-16 in Subjects With Moderate to Severe Distal Subungual Onychomycosis (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: SATO Pharmaceutical Co., Ltd.

Clinical • New P1 trial • Infectious Disease